Zimmermann S, Peters S, Owinokoko T et al (2018) Immune checkpoint inhibitors in the management of lung cancer. Am Soc Clin Oncol Educ Book 38:682–695

Article  PubMed  Google Scholar 

Ruffo E, Wu RC, Bruno TC et al (2019) Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol 42:101305 Elsevier

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kroemer G, Zitvogel L (2021) Immune checkpoint inhibitors. J Exp Med 218. https://doi.org/10.1084/jem.20201979

Onoi K, Chihara Y, Uchino J et al (2020) Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med 9:1362

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong SA, Liu SV (2019) Immune checkpoint inhibitors in small cell lung cancer: a partially realized potential. Adv Ther 36:1826–1832

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang DY, Salem J-E, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728

Article  PubMed  PubMed Central  Google Scholar 

Moreira A, Loquai C, Pföhler C et al (2019) Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer 106:12–23

Article  CAS  PubMed  Google Scholar 

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168

Article  CAS  PubMed  Google Scholar 

Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf. Accessed May 12, 2023

Thompson JA, Schneider BJ, Brahmer J et al (2019) Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 17:255–289

Article  CAS  Google Scholar 

Porcu M, De Silva P, Solinas C et al (2019) Immunotherapy associated pulmonary toxicity: biology behind clinical and radiological features. Cancers 11:305

Article  CAS  PubMed  PubMed Central  Google Scholar 

Disayabutr S, Calfee CS, Collard HR et al (2015) Interstitial lung diseases in the hospitalized patient. BMC Med 13:245

Article  PubMed  PubMed Central  Google Scholar 

Zhong L, Altan M, Shannon VR et al (2020) Immune-related adverse events: pneumonitis, immunotherapy. Springer, pp 255–269

Google Scholar 

Shannon VR, Anderson R, Blidner A et al (2020) Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer 28:6145–6157

Article  PubMed  PubMed Central  Google Scholar 

Tiu BC, Zubiri L, Iheke J et al (2022) Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer 10:e004670

Article  PubMed  PubMed Central  Google Scholar 

Atchley WT, Alvarez C, Saxena-Beem S et al (2021) Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 160:731–742

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sears CR, Peikert T, Possick JD et al (2019) Knowledge gaps and research priorities in immune checkpoint inhibitor–related pneumonitis. An official American thoracic society research statement. Am J Respir Crit Care Med 200:e31–e43

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taplitz RA, Kennedy EB, Bow EJ et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 36:3043–3054

Article  PubMed  Google Scholar 

Zhou S, Aitken SL (2023) Prophylaxis against Pneumocystis jirovecii pneumonia in adults. JAMA 330:182–183

Article  PubMed  Google Scholar 

Narum S, Westergren T, Klemp M (2014) Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 4:e004587

Article  PubMed  PubMed Central  Google Scholar 

Cook D, Guyatt G (2018) Prophylaxis against upper gastrointestinal bleeding in hospitalized patients. N Engl J Med 378:2506–2516

Article  CAS  PubMed  Google Scholar 

Thompson J, Schneider B, Brahmer J et al (2023) NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities version 1.2024- December 7, 2023. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed 4 Aug 2024

Chen EJ (2016) Being an oncology hospitalist. Hosp Med Clin 5:335–346

Article  Google Scholar 

Lodewijckx C, Decramer M, Sermeus W et al (2012) Eight-step method to build the clinical content of an evidence-based care pathway: the case for COPD exacerbation. Trials 13:229

Article  PubMed  PubMed Central  Google Scholar 

Deneckere S, Euwema M, Lodewijckx C et al (2013) Better interprofessional teamwork, higher level of organized care, and lower risk of burnout in acute health care teams using care pathways: a cluster randomized controlled trial. Med Care 51:99–107

Article  PubMed  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol: Off J Am Soc Clin Oncol 36:1714

Article  CAS  Google Scholar 

Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119–iv142

Article  CAS  PubMed  Google Scholar 

Rotter T, de Jong RB, Lacko SE et al (2019) Clinical pathways as a quality strategy. Improving healthcare quality in Europe. p 309

Wood LS (2019) Immune-related adverse events from immunotherapy: incorporating care step pathways to improve management across tumor types. J Adv Pract Oncol 10:47

PubMed  PubMed Central  Google Scholar 

Naidoo J, Reuss JE, Suresh K et al (2020) Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. J Immunother Cancer 8:e000984

Article  PubMed  PubMed Central  Google Scholar 

Middleton S, Barnett J, Reeves DS (2001) What is an integrated care pathway? Hayward Med Commun 3(3):1–8

Fayle SE, Palaskas NL, Siddiqui BA et al (2024) Development of a strategic initiative at MD Anderson cancer center to improve outcomes in immune-related adverse events. J Natl Compr Canc Netw 1:1–8

Google Scholar 

World Health Organization (2019) International statistical classification of diseases and related health problems (10th ed). https://icd.who.int/. Accessed 15 May 2023

Chuzi S, Tavora F, Cruz M et al (2017) Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. Cancer Manag Res 9:207

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shannon VR (2017) Pneumotoxicity associated with immune checkpoint inhibitor therapies. Curr Opin Pulm Med 23:305–316

Article  PubMed  Google Scholar 

Naidoo J, Wang X, Woo KM et al (2017) Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35:709

Article  CAS  PubMed  Google Scholar 

Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697

Article  CAS  PubMed